公司介绍 - Accuray公司在ESTRO 2024展示了最新一代的CyberKnife®和Radixact®平台，旨在提供医疗团队所需的技术，扩大放射治疗的治愈力量，并实现今年大会的重点，弥合护理差距[1] - Accuray公司与医疗保健专业人士和行业合作伙伴合作30年，开发了突破性技术，扩展了放射治疗的应用，并提供了精准和准确的CyberKnife和Radixact系统，使医疗团队能够个性化管理每位患者的癌症治疗过程[2] - Accuray公司在30年的发明和颠覆历史中引入了一些最新创新，这些创新已经成为放射治疗行业新标准，包括Radixact系统的内置CT扫描仪，ClearRT™增强成像以及CyberComm™和Cenos™等新物理产品[3][4][5][6]

 The new center is the most recent addition to the company's existing training hubs in Madison, Wisconsin (U.S.), Tokyo, Japan and Tianjin, China  Each facility offers a range of educational opportunities designed to advance patient care using the Accuray CyberKnife® and Radixact® Systems MADISON, Wis., April 18, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that as part of its commitment to advancing patient care the company has opened a new training center in Genolier, Switzer ...

公司现状 - Accuray (NASDAQ:ARAY)是一家备受关注的股票，尽管公司已经采取了许多明智的举措来改善其产品组合和增加增长前景，但市场份额增长却令人沮丧地缓慢，股价多年来一直徘徊不前，公司未能真正缩小与Varian（由西门子医疗（OTCPK:SMMNY）拥有）或Elekta（OTCPK:EKTAY）之间的差距。[1] - 公司的故事仍然与过去大致相同，关键问题是公司能否在进入更具价值定价的B型市场（价值约为6亿美元）时复制其在中国A型市场中占据的显著（市场领先）市场份额，并建立新的、更高的营收增长和扩大利润空间的标杆。尽管早期迹象是积极的，股价并不昂贵，但在经历了多年的虚假启动和缺乏进展后，这是一家需要“拭目以待”的公司。[3] 中国市场发展 - 中国市场对Accuray至关重要，公司已经在中国A型市场取得了相当大的成功，现在公司正在瞄准更大规模的B型市场。随着中国Tomo C系统订单开始涌入，包括中国44%的订单增长，这些系统在本财年第四季度开始交付，对财务报表的影响应该是显著的，为股价提供有意义的营收增长作为推动因素。[7] 市场竞争 - 在更具竞争力的市场中，Accuray正试图专注于升级和更新其已安装的基础设施，并争夺选择性的保险库份份额增长机会，特别是在对Accuray系统的高分段能力和新的自适应规划能力更感兴趣的情况下。[11]

财务表现 - Accuray Q2财报显示每股亏损10美分，较去年同期的每股亏损2美分扩大，也超过了Zacks Consensus Estimate的每股亏损7美分[3] - 第二季度财报显示Accuray的营收为1.072亿美元，同比下降6.6%，但略高于Zacks Consensus Estimate[4] - 净营收为1.06亿美元，同比下降8%[6] 营收构成 - 产品营收下降，服务营收有所增长，整体营收增长受到产品营收下降的影响[5] - Accuray的营收主要来自产品和服务两个方面[7] - 产品营收从去年同期的5150万美元下降了18.5%，主要是由于年度出货量减少[8] - 服务营收从去年同期的5570万美元增长了8.2%，主要受合同收入增加和安装、培训及备件销售量增加的推动[9] 费用和利润 - 毛利润下降16.4%至3590万美元，毛利率下降396个基点至33.5%[10] - 销售和市场费用下降16.4%至1140万美元，研发费用同比增长4.4%至1530万美元，总部和行政费用同比增长9.9%至1320万美元[11] - 第二季度运营亏损为390万美元，而去年同期运营利润为270万美元[12] 财务展望 - Accuray预计第三季度营收在1.12亿至1.18亿美元之间，全年营收预计在4.6亿至4.7亿美元之间，同比增长3-5%[16][17] - 分析师在过去两个月内没有发布任何盈利预期修订，共识预期由于这些变化而下调了100%[18]

Company to Take Part in Fireside Chat Tuesday, March 12, 2024 at 7:00am PST / 10:00am EST MADISON, Wis., Feb. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference taking place March 12-13, 2024. The management team is scheduled to participate in a fireside chat on Tuesday, March 12, 2024 at 7:00am PST / 10:00am EST. A live webcast of the fireside chat can be accessed on the Accuray website at in ...

While most financial advisors will probably steer you away from under $5 stocks, they have their benefits. Just like in football – the American kind – you can’t just run up the gut.Well, technically, you can. That’s where the phrase three yards and a cloud of dust basically originated. If you hold onto the ball and keep marching down the field, you eat up the clock and deny opportunities to your opposition. However, the problem with this rather unimaginative strategy is that stuff happens.And that stuff – t ...

公司前景展望 - Accuray Incorporated (ARAY)在未来几个季度有望实现增长，主要得益于其产品持续稳定的需求[1] - 公司在2024财年第二季度的表现和Precision Treatment Planning System (TPS)的潜力将进一步推动乐观情绪[1] - 然而，公司存在对技术的过度依赖和激烈的竞争[1]

Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is a center of excellence and recognized leader in the treatment of cancer in the province of Quebec The Radixact System is equipped with ClearRT™ and Synchrony®, advanced technologies designed to improve treatment outcomes for more patients each day MADISON, Wis., Feb. 13, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the team at Quebec's Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hosp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share ARAY The Nasdaq Stock Market LLC FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio ...

公司概况 - Accuray Incorporated宣布将参加BTIG MedTech、数字健康、生命科学和诊断工具会议[1] - Accuray致力于扩大放射治疗的潜力，为尽可能多的人提供改善生活的机会[3] - Accuray总部位于威斯康星州麦迪逊，拥有全球设施[3] 联系信息 - 投资者联系人为Aman Patel，媒体联系人为Beth Kaplan[4]